|
ANAPC13 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62447832963153E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
<1E-12 |
| Normal-vs-Stage2 |
1.77030000003686E-06 |
| Normal-vs-Stage3 |
1.11022302462516E-16 |
| Normal-vs-Stage4 |
1.62436730732907E-12 |
| Stage1-vs-Stage2 |
1.458050E-02 |
| Stage1-vs-Stage3 |
2.037900E-02 |
| Stage1-vs-Stage4 |
4.64389999998982E-06 |
| Stage2-vs-Stage3 |
4.814200E-04 |
| Stage2-vs-Stage4 |
6.58179999946107E-07 |
| Stage3-vs-Stage4 |
5.006400E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
4.03409999849558E-08 |
| Normal-vs-Asian |
2.02482475231136E-12 |
| Caucasian-vs-AfricanAmerican |
7.432800E-01 |
| Caucasian-vs-Asian |
1.607210E-01 |
| AfricanAmerican-vs-Asian |
7.047800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.11022302462516E-15 |
| Normal-vs-Female |
1.62436730732907E-12 |
| Male-vs-Female |
8.836000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62458935193399E-12 |
| Normal-vs-Age(41-60Yrs) |
8.88178419700125E-16 |
| Normal-vs-Age(61-80Yrs) |
1.65711888655551E-12 |
| Normal-vs-Age(81-100Yrs) |
6.02519999999274E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.814400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
9.129200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.619400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.687400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.851600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.114000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.386360E-04 |
| Classical-VS-Follicular |
1.01639807681408E-11 |
| Classical-VS-Other |
8.286400E-01 |
| Classical-VS-Normal |
1.62447832963153E-12 |
| Tall-VS-Follicular |
5.55111512312578E-16 |
| Tall-VS-Other |
3.586200E-02 |
| Tall-VS-Normal |
<1E-12 |
| Follicular-VS-Other |
3.526500E-02 |
| Follicular-VS-Normal |
1.164510E-03 |
| Other-VS-Normal |
6.12209999999447E-05 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
7.49844630831831E-13 |
| Normal-vs-N1 |
<1E-12 |
| N0-vs-N1 |
1.6063899999974E-05 |
|
|
